GLP-1 Inhibitors in HFpEF With Obesity: Are We There Yet? GLP-1 Inhibitors in HFpEF With Obesity: Are We There Yet?

Obesity, a driver of inflammation, is prevalent in patients with HFpEF. Ileana Pina asks Ambarish Pandey about GLP-1 inhibitors and SGLT2 inhibitors in HFpEF. Are these drugs anti-inflammatory?theheart.org on Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Commentary Source Type: news